Abstract
Introduction: Interleukins and cytokines play an important role in the pathogenesis of many cancers. We aimed to evaluate the interleukin (IL)-6 gene polymorphisms in patients with papillary thyroid carcinoma (PTC) and control subjects. Material and methods: In this study, 42 patients with PTC and 340 healthy controls were included. Peripheral blood samples were taken from control group and patients, and blood samples were preserved at −80 C in tubes containing Na-EDTA. Results: We also found a statistically significant difference between patients with PTC and the control group with respect to IL-6 genotype (p<0.05). IL-6 gene polymorphism in patients with PTC patients did not reveal statistically significant difference between the 2 groups (size of tumor >1 cm and <1 cm), multicentricity, RET-PTC types and capsule invasion (p>0.05). We also did not find a statistically significant difference between patients with PTC and the control group with respect to IL-6-gene allele frequency (p>0.05). Discussion: Our data suggest that the IL-6 G-174 C polymorphism could play a role in thyroid cancer risk, but there is no effective role as a prognostic factor.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Rosai J, Carcangiu ML, DeLellis RA. Atlas of tumor pathology: tumors of the thyroid gland. 3rd series. Washington DC: Armed Forces Institute of Pathology. 1992, p. 343.
Sheils O. Molecular classification and biomarker discovery in papillary thyroid carcinoma. Expert Rev Mol Diagn 2005, 5: 927–46.
Finn SP, Smyth P, O’Leary J, Sweeney EC, Sheils O. Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 938–41.
Balasubramanian SP, Azmy IA, Higham SE, et al. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 2006, 6: 188.
El-Omar EM, Rabkin CS, Gammon MD, et al. Increased risk of non-cardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003, 124: 1193–201.
Hefler LA, Grimm C, Ackermann S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res 2003, 63: 3066–8.
Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004, 90: 419–22.
Yamamoto T, Matsuda T, Junicho A, Kishi H, Saatcioglu F, Muraguchi A. Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett 2000, 486: 143–8.
Belluco C, Olivieri F, Bonafe M, et al. -174 G >C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 2003, 9: 2173–6.
Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999, 19: 1427–32.
Fishman D, Faulds G, Jeffery, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102: 1369–76.
Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 2000, 85: 1334–9.
Hengartner MO. The biochemistry of apoptosis. Nature 2000, 407: 770–6.
Ruggeri RM, Villari D, Simone A, et al. Co-expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J Endocrinol Invest 2002, 25: 959–66.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001, 357: 539–45.
Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102: 1369–76.
Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000, 275: 18138–44.
Belluco C, Olivieri F, Bonafe M, et al. -174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 2003, 9: 2173–6.
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6-174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001, 22: 2243–52.
Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002, 13: 3–16.
Finn SP, Smyth P, O’Leary J, Sweeney EC, Sheils O. Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88: 938–41.
Cetta F, Gori M, Montalto G, Zuckermann M, Toti P. Different significance of ret/PTC(1) and ret/PTC(3) rearrangements in thyroid carcinogenesis: lesson from two subgroups of patients with papillary thyroid carcinomas showing the highest incidence of ret/PTC activation. J Clin Endocrinol Metab 2001, 86: 1429.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Özgen, A.G., Karadeniz, M., Erdogan, M. et al. The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients. J Endocrinol Invest 32, 491–494 (2009). https://doi.org/10.1007/BF03346494
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346494